Evidence map›Paper›PMID 34705155›Full record

ReviewMolecular diversity2022

Montmorillonite clay-based heterogenous catalyst for the synthesis of nitrogen heterocycle organic moieties: a review.

Thangapandi Chellapandi, Gunabalan Madhumitha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thangapandi ChellapandiChemistry of Heterocycles & Natural Product Research Laboratory, Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamilnadu, 632014, India.
Gunabalan MadhumithaChemistry of Heterocycles & Natural Product Research Laboratory, Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamilnadu, 632014, India. madhumitha.g@vit.ac.in.ORCID http://orcid.org/0000-0002-5343-1563

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of montmorillonite clay as solid catalyst has grabbed much attention in the liquid phase reactions for organic synthesis. In recent years, there has been a lot of interest in organic synthesis using montmorillonite-based composites, especially in the synthesis of heterogeneous nanoparticles. Due to the robust and green nature of montmorillonite-based nanocatalysts, it has been widely used in N-heterocyclic reactions. In this review, we have concentrated on the reports pertaining the use of montmorillonite-based nanocatalyst in the synthesis of N-heterocycles, a category of organic compounds with excellent biological properties. This manuscript is arranged by the types of N-containing heterocycles synthesized using montmorillonite-based composite as catalysts including polycyclic spirooxindoles, heterocyclic propargylamine, indole-based heterocycles, quinoline and its derivatives, six-membered N-heterocyclic-based compounds and five-membered N-heterocyclic-based compounds. Special attention was given to the structural stability under experimental parameters of the montmorillonite-based composite with the incidence of metal leaching and reusability. Finally, along with recent developments, new findings in heterogeneous montmorillonite (Mt)-based catalysis have also been addressed.

Indexed as

Heterocyclic CompoundsNitrogenBentoniteCatalysisClayBentoniteClayHeterocyclic CompoundsNitrogenHeterocycles synthesisHeterogeneous catalysisMontmorilloniteNanocatalystOrganic synthesis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.